Since sorafenib's approval in 2008 for advanced HCC, the landscape of systemic therapy remained largely unchanged for nearly a decade, with no breakthroughs emerging during this period. However, in ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

David M. Dudzinski: A 59-year-old man with a history of obesity, dyslipidemia, and hypertension was evaluated in the oncology clinic of this hospital because of hepatocellular carcinoma.

LIVER cancer is the fourth most common cancer in Malaysia and also the fourth leading cause of cancer-related deaths.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Advanced hepatocellular carcinoma (HCC) with pulmonary metastasis (PM) has a poor prognosis, and optimal treatment strategies remain controversial. This study compared pulmonary metastasectomy and ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.